Literature DB >> 28346056

Alcohol and Drug Use and Aberrant Drug-Related Behavior Among Patients on Chronic Opioid Therapy.

Cynthia I Campbell1,2, Andrea H Kline-Simon1, Michael Von Korff3, Kathleen W Saunders3, Constance Weisner1,2.   

Abstract

OBJECTIVE: To better identify individuals on chronic opioid therapy (COT) at high risk for aberrant-drug related behavior (ADRB). We examine whether patients with low level alcohol and drug use have similar characteristics to those with alcohol and drug disorders. We then examined the relationship of alcohol and drug use to ADRBs among COT patients.
METHODS: The sample was 972 randomly selected COT patients (age 21-80 years old) from a large health system in Northern California, USA, and interviewed in 2009. Logistic regression models were used to model the dependent variables of: alcohol use, illicit drug use, alcohol disorders, illicit drug disorders, and ADRBs.
RESULTS: The odds of daily/weekly alcohol use were lower for those with a high daily opioid dose (120+ mg/day vs. <20 mg/day) (OR = 0.32, p < 0.010). Illicit drug disorders were associated with depression (OR = 2.31, p < .001) and being on a high daily opioid dose (OR = 5.51, p < .01). Participants with illicit drug use had higher odds of giving (OR = 2.57, p < 0.01) and receiving opioids from friends or family (OR = 3.25, p < 0.001), but disorder diagnoses were not associated with ADRBs.
CONCLUSIONS: Findings reinforce that illicit drug use should be of high concern to clinicians prescribing opioids, and suggest it should be considered separately from alcohol use and alcohol disorders in the evaluation of ADRBs. Frequent alcohol use is low, but not uncommon, and suggests a need to discuss specific issues regarding safe use of opioids among persons who use alcohol that may differ from their risk of drug use.

Entities:  

Keywords:  Alcohol use; aberrant drug related behavior; alcohol disorder; chronic opioid therapy; drug disorder; drug use

Mesh:

Substances:

Year:  2017        PMID: 28346056      PMCID: PMC5834235          DOI: 10.1080/10826084.2016.1276189

Source DB:  PubMed          Journal:  Subst Use Misuse        ISSN: 1082-6084            Impact factor:   2.164


  44 in total

1.  Concurrent use of alcohol and sedatives among persons prescribed chronic opioid therapy: prevalence and risk factors.

Authors:  Kathleen W Saunders; Michael Von Korff; Cynthia I Campbell; Caleb J Banta-Green; Mark D Sullivan; Joseph O Merrill; Constance Weisner
Journal:  J Pain       Date:  2012-01-29       Impact factor: 5.820

2.  Feeling no pain: alcohol as an analgesic.

Authors:  Kenneth M Woodrow; Lorne G Eltherington
Journal:  Pain       Date:  1988-02       Impact factor: 6.961

3.  Schedules of controlled substances: rescheduling of hydrocodone combination products from schedule III to schedule II. Final rule.

Authors: 
Journal:  Fed Regist       Date:  2014-08-22

4.  Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Kevin P Conway; Wilson Compton; Frederick S Stinson; Bridget F Grant
Journal:  J Clin Psychiatry       Date:  2006-02       Impact factor: 4.384

5.  Chronic spinal pain and physical-mental comorbidity in the United States: results from the national comorbidity survey replication.

Authors:  Michael Von Korff; Paul Crane; Michael Lane; Diana L Miglioretti; Greg Simon; Kathleen Saunders; Paul Stang; Nancy Brandenburg; Ronald Kessler
Journal:  Pain       Date:  2005-02       Impact factor: 6.961

6.  Aberrant drug-related behaviors: a qualitative analysis of medical record documentation in patients referred to an HIV/chronic pain clinic.

Authors:  Jessica S Merlin; Janet M Turan; Ivan Herbey; Andrew O Westfall; Joanna L Starrels; Stefan G Kertesz; Michael S Saag; Christine S Ritchie
Journal:  Pain Med       Date:  2014-08-19       Impact factor: 3.750

7.  Self-report of alcohol use for pain in a multi-ethnic community sample.

Authors:  Joseph L Riley; Christopher King
Journal:  J Pain       Date:  2009-09       Impact factor: 5.820

Review 8.  Behavioral counseling after screening for alcohol misuse in primary care: a systematic review and meta-analysis for the U.S. Preventive Services Task Force.

Authors:  Daniel E Jonas; James C Garbutt; Halle R Amick; Janice M Brown; Kimberly A Brownley; Carol L Council; Anthony J Viera; Tania M Wilkins; Cody J Schwartz; Emily M Richmond; John Yeatts; Tammeka Swinson Evans; Sally D Wood; Russell P Harris
Journal:  Ann Intern Med       Date:  2012-11-06       Impact factor: 25.391

9.  De facto long-term opioid therapy for noncancer pain.

Authors:  Michael Von Korff; Michael Von Korff; Kathleen Saunders; Gary Thomas Ray; Denise Boudreau; Cynthia Campbell; Joseph Merrill; Mark D Sullivan; Carolyn M Rutter; Michael J Silverberg; Caleb Banta-Green; Constance Weisner
Journal:  Clin J Pain       Date:  2008 Jul-Aug       Impact factor: 3.442

10.  Reported lifetime aberrant drug-taking behaviors are predictive of current substance use and mental health problems in primary care patients.

Authors:  Michael F Fleming; James Davis; Steven D Passik
Journal:  Pain Med       Date:  2008-08-18       Impact factor: 3.750

View more
  4 in total

1.  Prescription opioid use before and after kidney transplant: Implications for posttransplant outcomes.

Authors:  K L Lentine; N N Lam; A S Naik; D A Axelrod; Z Zhang; V R Dharnidharka; G P Hess; D L Segev; R Ouseph; H Randall; T Alhamad; R Devraj; R Gadi; B L Kasiske; D C Brennan; M A Schnitzler
Journal:  Am J Transplant       Date:  2018-04-17       Impact factor: 8.086

2.  Prescription opioid use before and after heart transplant: Associations with posttransplant outcomes.

Authors:  Krista L Lentine; Kevin S Shah; Jon A Kobashigawa; Huiling Xiao; Zidong Zhang; David A Axelrod; Ngan N Lam; Dorry L Segev; Mara Ann McAdams-DeMarco; Henry Randall; Gregory P Hess; Hui Yuan; Luke S Vest; Bertram L Kasiske; Mark A Schnitzler
Journal:  Am J Transplant       Date:  2019-09-12       Impact factor: 8.086

3.  Pain Severity and Interference and Substance Use Among Community Pharmacy Patients Prescribed Opioids: A Secondary Analysis of the PHARMSCREEN Study.

Authors:  Elizabeth Charron; Akiko Okifuji; M Aryana Bryan; Sarah Reese; Jennifer L Brown; Andrew Ferguson; Udi E Ghitza; T Winhusen; Gerald Cochran
Journal:  J Pain       Date:  2022-04-11       Impact factor: 5.383

4.  Survival implications of prescription opioid and benzodiazepine use in lung transplant recipients: Analysis of linked transplant registry and pharmacy fill records.

Authors:  Krista L Lentine; Paolo R Salvalaggio; Yasar Caliskan; Ngan N Lam; Mara McAdams-DeMarco; David Axelrod; Dorry L Segev; Larissa Myaskovsky; Mary Amanda Dew; Heather Bruschwein; Deborah J Levine; Stuart Sweet; Gregory P Hess; Bertram L Kasiske; Mark A Schnitzler
Journal:  J Heart Lung Transplant       Date:  2021-02-17       Impact factor: 13.569

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.